Clinical and molecular characteristics associated with megakaryocytic dysplasia in patients with myelodysplastic syndromes

Objectives Megakaryocytic dysplasia (MegDys) is a common morphologic abnormality in myelodysplastic syndromes (MDS), but its clinical and molecular significance remains incompletely understood. We characterized hematologic, cytogenetic, and mutational features associated with MegDys and identified independent associations after risk adjustment.Methods A total of 169 patients with MDS (2022 WHO classification) were retrospectively classified into MegDys-positive (n = 89) and MegDys-negative (n = 80) groups based on bone marrow morphology. Clinical, hematologic, cytogenetic, and targeted sequencing data were compared between groups, with the false discovery rate (FDR) controlled by the Benjamini–Hochberg method. Multivariable Firth logistic regression was performed, adjusting for blast percentage, complex karyotype, MDS subtype, age, sex, and mutation status.Results MegDys+ patients exhibited lower peripheral blood counts, higher bone marrow blast percentages, and enrichment of RUNX1, EZH2, and CBL mutations, whereas SF3B1 mutations were more frequent in MegDys − patients (all FDR-corrected P < 0.05). In multivariable analysis, EZH2 mutation was the only factor independently associated with MegDys (adjusted OR = 3.38, 95% CI: 1.12–12.03, P = 0.030); RUNX1 and CBL showed suggestive but non-significant associations (aOR: 2.69 and 3.15), indicating that their enrichment was largely attributable to the higher-risk disease context.Discussion MegDys is not merely a morphological correlate of high-risk MDS: EZH2 retained an independent association after risk adjustment, whereas the signals for RUNX1 and CBL were largely explained by confounding.Validation in larger cohorts is warranted.Conclusions MegDys is characterized by severe thrombopoietic abnormalities, high-risk disease features, and distinct mutation enrichment patterns. After risk adjustment, EZH2 mutation emerged as the sole independent molecular correlate of MegDys.

Authors

Institutions

Publication Details

Journal
Hematology
Published
2026-11-17
DOI
https://doi.org/10.1080/16078454.2026.2763294
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical and molecular characteristics associated with megakaryocytic dysplasia in patients with myelodysplastic syndromes

Zhengrong Liu, Xiaojie Liu, Deju Wan
1 links
Hematology
Acute Myeloid Leukemia Research
article

Clinical and molecular characteristics associated with megakaryocytic dysplasia in patients with myelodysplastic syndromes

Zhengrong Liu, Xiaojie Liu, Deju Wan
article en

Abstract

Objectives Megakaryocytic dysplasia (MegDys) is a common morphologic abnormality in myelodysplastic syndromes (MDS), but its clinical and molecular significance remains incompletely understood. We characterized hematologic, cytogenetic, and mutational features associated with MegDys and identified independent associations after risk adjustment.Methods A total of 169 patients with MDS (2022 WHO classification) were retrospectively classified into MegDys-positive (n = 89) and MegDys-negative (n = 80) groups based on bone marrow morphology. Clinical, hematologic, cytogenetic, and targeted sequencing data were compared between groups, with the false discovery rate (FDR) controlled by the Benjamini–Hochberg method. Multivariable Firth logistic regression was performed, adjusting for blast percentage, complex karyotype, MDS subtype, age, sex, and mutation status.Results MegDys+ patients exhibited lower peripheral blood counts, higher bone marrow blast percentages, and enrichment of RUNX1, EZH2, and CBL mutations, whereas SF3B1 mutations were more frequent in MegDys − patients (all FDR-corrected P < 0.05). In multivariable analysis, EZH2 mutation was the only factor independently associated with MegDys (adjusted OR = 3.38, 95% CI: 1.12–12.03, P = 0.030); RUNX1 and CBL showed suggestive but non-significant associations (aOR: 2.69 and 3.15), indicating that their enrichment was largely attributable to the higher-risk disease context.Discussion MegDys is not merely a morphological correlate of high-risk MDS: EZH2 retained an independent association after risk adjustment, whereas the signals for RUNX1 and CBL were largely explained by confounding.Validation in larger cohorts is warranted.Conclusions MegDys is characterized by severe thrombopoietic abnormalities, high-risk disease features, and distinct mutation enrichment patterns. After risk adjustment, EZH2 mutation emerged as the sole independent molecular correlate of MegDys.

HematologyVol. 31(1)
Henan Medical University (CN)
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon